EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway

Jinyao Zhang, Yuze Shi, Ke Ding, Weiwei Yu, Jianbo He, Beicheng Sun

Journal of Experimental & Clinical Cancer Research · 06.05.2024 · 43 (1)

DOI: 10.1186/s13046-024-03055-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental & Clinical Cancer Research, online erschienen am 06.05.2024. Verfasst von Jinyao Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Me…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Disease Progression, Liver Neoplasms, Neoplasm Metastasis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the State Key Program of National Natural Science Foundation, the Key Research and Development Program of AnHui Province, the Program of Department of Education of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is a fatal malignancy with poor prognosis due to lack of effective clinical interference. DCAF1 plays a vital role in regulating cell growth and proliferation, and is involved in the progression of various malignancies. However, the function of DCAF1 in HCC development and the underlying mechanism are still unknown. This study aimed to explore the effect of DCAF1 in HCC and the corresponding molecular mechanism.

Methods

Quantitative real-time PCR, Western blot and immunostaining were used to determine DCAF1 expression in tumor tissues and cell lines. Subsequently, in vitro and in vivo experiments were conducted to explore the function of DCAF1 in tumor growth and metastasis in HCC. Coimmunoprecipitation, mass spectrometry and RNA sequencing were performed to identify the underlying molecular mechanisms.

Results

In this study, we found that DCAF1 was observably upregulated and associated with poor prognosis in HCC. Knockdown of DCAF1 inhibited tumor proliferation and metastasis and promoted tumor apoptosis, whereas overexpressing DCAF1 yielded opposite effects. Mechanistically, DCAF1 could activate the Akt signaling pathway by binding to PARD3 and enhancing its expression. We also found that the combined application of DCAF1 knockdown and Akt inhibitor could significantly suppress subcutaneous xenograft tumor growth.

Conclusions

Our study illustrates that DCAF1 plays a crucial role in HCC development and the DCAF1/PARD3/Akt axis presents a potentially effective therapeutic strategy for HCC. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularDisease ProgressionLiver NeoplasmsNeoplasm MetastasisProto-Oncogene Proteins c-aktSignal TransductionAnimalsFemaleHumansMaleMiceAdaptor Proteins, Signal TransducingApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticMice, NudePrognosisXenograft Model Antitumor AssaysCell Cycle ProteinsProtein Serine-Threonine KinasesUbiquitin-Protein Ligases

Stichwörter der Autor:innen

AktDCAF1Hepatocellular carcinomaPARD3

Substanzen

Adaptor Proteins, Signal TransducingProto-Oncogene Proteins c-aktPARD3 protein, humanCell Cycle ProteinsDCAF1 protein, humanProtein Serine-Threonine KinasesUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Graduate School, Nanjing, Jiangsu Province, 210008, Chin…
  • Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, 210008, China.
  • Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu Province, 210008, China.
  • Department of Thoracic and Cardiovascular Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, 210008, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, 230022, China. sunbc@nju.edu.cn.

Förderung

  • the State Key Program of National Natural Science Foundation
  • the Key Research and Development Program of AnHui Province
  • the Program of Department of Education of Anhui Province

Zitieren

APA

Zhang, J., Shi, Y., Ding, K., Yu, W., He, J., & Sun, B. (2024). DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway. Journal of Experimental & Clinical Cancer Research, 43(1). https://doi.org/10.1186/s13046-024-03055-2

Vancouver

Zhang J, Shi Y, Ding K, Yu W, He J, Sun B. DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway. Journal of Experimental & Clinical Cancer Research. 2024;43(1). doi:10.1186/s13046-024-03055-2

BibTeX
@article{Zhang2024,
  author = {Zhang, Jinyao and Shi, Yuze and Ding, Ke and Yu, Weiwei and He, Jianbo and Sun, Beicheng},
  title = {DCAF1 interacts with PARD3 to promote hepatocellular carcinoma progression and metastasis by activating the Akt signaling pathway},
  journal = {Journal of Experimental & Clinical Cancer Research},
  year = {2024},
  volume = {43},
  number = {1},
  doi = {10.1186/s13046-024-03055-2}
}
Kostenlos starten →